Delivering precision antimicrobial therapy through closed-loop control systems

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 4, 2018, Pages 835-843

  Rawson, T M ^a   O'Hare, D ^b   Herrero, P ^b   Sharma, S ^c   Moore, L S P ^a,d   de Barra, E ^d   Roberts, J A ^e,f   Gordon, A C ^b   Hope, W ^g   Georgiou, P ^b   Cass, A E G ^b   Holmes, A H ^a,d  

^a Imperial College London ^*  (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CONTROL SYSTEM; DRUG DELIVERY SYSTEM; HUMAN; INDIVIDUALIZATION; INTERSTITIAL FLUID; NONHUMAN; PERSONALIZED MEDICINE; TREATMENT OUTCOME; DRUG MONITORING; DRUG THERAPY; DRUG UTILIZATION; GENETIC PROCEDURES; PROCEDURES; STANDARDS;

ANTI-BACTERIAL AGENTS; BIOSENSING TECHNIQUES; DRUG MONITORING; DRUG THERAPY; DRUG UTILIZATION; HUMANS; PRECISION MEDICINE;

EID: 85044863561     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx458     Document Type: Article

References (122)

1. O'Neill J. 2016. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. https://amr-review.org/sites/default/files/160518_Final% 20paper_with%20cover.pdf.
2. Holmes AH, Moore LSP, Sundsfjord A, et al. Understanding themechanisms and drivers of antimicrobial resistance. Lancet 2016; 387: 176-87.
3. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
4. Perez F, El Chakhtoura NG, Papp-Wallace K, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply 'precision medicine' to antimicrobial chemotherapy? Expert Opin Pharmacother 2016; 17: 761-81.
5. Abdul-AzizMH, Roberts JA, Lipman J, et al. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015; 36: 136-53.
6. Cotta MO, Roberts JA, Lipman J. We need to optimize piperacillintazobactam dosing in critically ill patients-but how? Crit Care 2016; 20: 163.
7. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011; 1: 47.
8. Charmillon A, Novy E, Agrinier N, et al. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for b-lactam administration and therapeutic drug monitoring among critically ill patients in France. Clin Microbiol Infect 2016; 22: 625-31.
9. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of b-lactams. Crit Care 2011; 15: R206.
10. Huttner A, Harbarth S, Hope WWet al. Therapeutic drug monitoring of the b-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 2015; 70: 3178-83.
11. Patel BM, Paratz J, See NC, et al. Therapeutic drug monitoring of b-lactam antibiotics in burns patients-a one-year prospective study. Ther Drug Monit 2012; 34: 160-4.
12. Roberts JA, Norris R, Paterson DL, et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36.
13. Roberts JA, Paul SK, AkovaMet al. DALI: Defining antibiotic levels in intensive care unit patients: Are currentb-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
14. FeltonTW, Roberts JA, LodiseTPet al. Individualization of piperacillin dosing for critically ill patients: Dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother 2014; 58: 4094-102.
15. Carlier M, Stove V, Wallis SC, et al. Assays for therapeutic drug monitoring of b-lactam antibiotics: a structured review. Int J Antimicrob Agents 2015; 46: 367-75.
16. Souza MJ, Kulmann RR, Silva LM, et al. Development and in-house validation of a microbiological assay for determination of cefepime in injectable preparations.JAOAC Int 2006; 89: 1367-72.
17. PickeringMK, Brown SD. Assays for determination of ertapenemfor applications in therapeutic drug monitoring, pharmacokinetics and sample stability. Biomed Chromatogr 2014; 28: 1525-31.
18. Miranda Bastos AC, Vandecasteele SJ, Tulkens PM, et al. Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. J Pharm Biomed Anal 2014; 90: 192-7.
19. Zalewski P, Cielecka-Piontek J, Paczkowska M. Development and validation of stability-indicating HPLC method for simultaneous determination of meropenemand potassium clavulanate. Acta Pol Pharm 2014; 71: 255-60.
20. Wolff F, Deprez G, Seyler L, et al. Rapid quantification of six b-lactams to optimize dosage regimens in severely septic patients. Talanta 2013; 103: 153-60.
21. Rawson TM, Moore LS, Hernandez B, et al. A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately? Clin Microbiol Infect 2017; 23: 524-32.
22. Wilhelm AJ, den Burger JCG, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet 2014; 53: 961-73.
23. Chong H. Paper-based microfluidic point-of-care diagnostic devices for monitoring drug metabolism. J Nanomed Biotherapeut Discov 2013; 3: 1-2.
24. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med 2009; 24: 1-10.
25. Parker SL, Dorofaeff T, Lipman J, et al. Is there a role for microsampling in antibiotic pharmacokinetic studies? Expert Opin Drug Metab Toxicol 2016; 5255: 601-14.
26. Rawson TM, Sharma S, Georgiou P, et al. Towards a Minimally Invasive Device for b-lactam Monitoring in Humans. 2017. http://ac.els-cdn.com/S1388 248117301856/1-s2.0-S1388248117301856-main.pdf?_tid"8511cda4-7048 -11e7-976d-00000aab0f02&acdnat"1500884423_b35db9176145fbd9ccc6 2d4a0c7c1c04.
27. Reddy M, Herrero P, Sharkawy ME, et al. Metabolic control with the bioinspired artificial pancreas in adults with type 1 diabetes: a 24-hour randomized controlled crossover study. J Diabetes Sci Technol 2016; 10: 405-13.
28. Sharma S, Huang Z, Rogers M, et al. Evaluation of a minimally invasive glucose biosensor for continuous tissue monitoring. Anal Bioanal Chem 2016; 408: 8427-35.
29. Yan G, Warner KS, Zhang J, et al. Evaluation needle length and density of microneedle arrays in the pretreatment of skin for transdermal drug delivery. Int J Pharm2010; 391: 7-12.
30. Bariya SH, GohelMC,Mehta TA, et al.Microneedles: an emerging transdermal drug delivery system. J PharmPharmacol 2012; 64: 11-29.
31. Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2016; 10: 714-23.
32. Absalom AR, Sutcliffe N, Kenny GN. Closed-loop control of anesthesia using bispectral index. Anesthesiology 2002; 96: 67-73.
33. Madhavan JS, Puri GD, Mathew PJ. Closed-loop isoflurane administration with bispectral index in open heart surgery: randomized controlled trial with manual control. Acta Anaesthesiol Taiwan 2011; 49: 130-5.
34. El-Laboudi A, Oliver NS, Cass A, et al. Use of microneedle array devices for continuous glucose monitoring: a review. Diabetes Technol Ther 2013; 15: 101-15.
35. Trzebinski J, Sharma S, Radomska-Botelho Moniz A, et al. Microfluidic device to investigate factors affecting performance in biosensors designed for transdermal applications. Lab Chip 2012; 12: 348.
36. Roberts JA, Udy AA, Jarrett P, et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother 2014; 70: 1495-502.
37. Johnson BL, Damer KM, Walroth TA, et al. A systematic review of vancomycin dosing and monitoring in burn patients. J Burn Care Res 2015; 36: 641-50.
38. Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
39. Vincent J-L, Bassetti M, François B, et al. Advances in antibiotic therapy in the critically ill. Crit Care 2016; 20: 133.
40. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of b-lactams may account for therapeutic failure in patients with septic shock. Crit CareMed 2001; 29: 385-91.
41. Johnson MA, Moradi MH, eds. PID Control. London: Springer, 2005. http:// link.springer.com/10.1007/1-84628-148-2.
42. Ahn H-S, Chen Y, Moore KL. Iterative Learning Control. London: Springer London, 2007. http://link.springer.com/10.1007/978-1-84628-859-3.
43. Wang Y, Gao F, Doyle FJ. Survey on iterative learning control, repetitive control, and run-to-run control. J Process Control 2009; 19: 1589-600.
44. Madady A. PID type iterative learning control with optimal gains. Int J Control AutomSyst 2008; 6: 194-203.
45. Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2013; 65: 1053-90.
46. Frimodt-Møller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 2002; 19: 333-9.
47. Huurneman LJ, NeelyM, Veringa A, et al. Pharmacodynamics of voriconazole in children: Further steps along the path to true individualized therapy. Antimicrob Agents Chemother 2016; 60: 2336-42.
48. Ramos-Martín V, Neely MN, McGowan P, et al. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates:making better use of C-reactive protein to deliver individualized therapy. J Antimicrob Chemother 2016; 71: 3168-78.
49. Henry S, McAllister DV, Allen MG, et al. Microfabricated microneedles: a novel approach to transdermal drug delivery. J PharmSci 1998; 87: 922-5.
50. Sharma S, Saeed A, Johnson C, et al. Rapid, low cost prototyping of transdermal devices for personal healthcare monitoring. Sens Biosensing Res 2017; 13: 104-8.
51. Moniz ARB, Michelakis K, Trzebinski J, et al. Minimally invasive enzyme microprobes: an alternative approach for continuous glucose monitoring. J Diabetes Sci Technol 2012; 6: 479-80.
52. Kim YC, Park JH, Prausnitz MR.Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64: 1547-68.
53. Ranamukhaarachchi SA, Padeste C, Dübner M, et al. Integrated hollow microneedle-optofluidic biosensor for therapeutic drug monitoring in subnanoliter volumes. Sci Rep 2016; 6: 29075.
54. Ferguson BS, Hoggarth DA, Maliniak D, et al. Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. Sci Transl Med 2013; 5: 213ra165.
55. Lee H, Song C, Hong YS, et al. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug deliverymodule. Sci Adv 2017; 3: e1601314.
56. Hayat A, Marty JL. Aptamer based electrochemical sensors for emerging environmental pollutants. Front Chem 2014; 2: 41.
57. Gorchkov DV, Soldatkin AP, Maupas H, et al. Correlation between the electrical charge properties of polymeric membranes and the characteristics of ion field effect transistors or penicillinase based enzymatic field effect transistors. Anal Chim Acta 1996; 331: 217-23.
58. Healey BG, Walt DR. Improved fiber-optic chemical sensor for penicillin. Anal Chem1995; 67: 4471-6.
59. Lee SR, Rahman MM, Sawada K, et al. Fabrication of a highly sensitive penicillin sensor based on charge transfer techniques. Biosens Bioelectron 2009; 24: 1877-82.
60. O'Hare D. Biosensors and sensor systems. In: G Yang, ed. Body Sensor Networks. Springer, 2014. http://link.springer.com/10.1007/978-1-4471-6374-9.
61. Trouillon R, Combs Z, Patel BA, et al. Comparative study of the effect of various electrode membranes on biofouling and electrochemical measurements. Electrochem Commun2009; 11: 1409-13.
62. Herrero P, Georgiou P, Oliver N, et al. A bio-inspired glucose controller based on pancreatic b-cell physiology. J Diabetes Sci Technol 2012; 6: 606-16.
63. Philip A, Rawson TM, Moore LSP, et al. Closed-loop controller systems for the precision delivery of vancomycin: an in silico proof-of-concept. In: Federation of Infection Society Annual Conference, 2016. Abstract 5121. http:// www.journalofhospitalinfection.com/article/S0195-6701(16)30516-3/pdf.
64. Ulldemolins M, Vaquer S, Llauradó-Serra M, et al. b-Lactam dosing in critically ill patientswith septic shock and continuous renal replacement therapy. Crit Care 2014; 18: 227.
65. CataldoMA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic reviewandmeta-analysis. J Antimicrob Chemother 2012; 67: 17-24.
66. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospectivemulticenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
67. UlldemolinsM,Martin-Loeches I, Llaurado-SerraMet al. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. J Antimicrob Chemother 2016; 71: 1651-9.
68. Roberts JA, Lipman J, Blot S, et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14: 390-6.
69. Roos JF, Lipman J, Kirkpatrick CMJ. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gramnegative bacteria. IntensiveCareMed2007; 33: 781-8.
70. Ramos-Martín V, Johnson A, Livermore J, et al. Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin inneonates. J Antimicrob Chemother 2016; 992-1002.
71. Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 2015; 19: 28.
72. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. AmJ Physiol Renal Physiol 2000; 278: F817-22.
73. ShimamotoY, FukudaT, TanakaKet al. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive CareMed 2013; 39: 1247-52.
74. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient -Concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 2014; 77: 3-11.
75. Herrero P, Pesl P, Reddy M, et al. Advanced insulin bolus advisor based on run-to-run control and case-based reasoning. IEEE J Biomed Heal Informatics 2015; 19: 1087-96.
76. Phua J, NgerngW, See K, et al. Characteristics and outcomes of culturenegative versus culture-positive severe sepsis. Crit Care 2013; 17: R202.
77. Zarb P, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. Drugs 2011; 71: 745-55.
78. Rawson TM, Charani E, Moore LSP, et al. Mapping the decision pathways of acute infection management in secondary care among UKmedical physicians: a qualitative study. BMCMed 2016; 14: 208.
79. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16: 819-27.
80. Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis 2015; 2: ofv098.
81. Kobeissi ZA, Zanotti-Cavazzoni SL. Biomarkers of sepsis. Yearb Crit Care Med 2010; 2010: 227-8.
82. Nargis W, Ahamed B, Ibrahim M. Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient. Int J Crit Illn Inj Sci 2014; 4: 195.
83. Nagaraj VJ, Jacobs M, Vattipalli KM, et al. Nanochannel-based electrochemical sensor for the detection of pharmaceutical contaminants in water. Environ Sci Process Impacts 2013; 16: 135-40.
84. Zhang K, Lu L, Wen Y, et al. Facile synthesis of the necklace-like graphene oxide-multi-walled carbon nanotube nanohybrid and its application in electrochemical sensing of Azithromycin. Anal Chim Acta 2013; 787: 50-6.
85. Pinacho DG, Sánchez-Baeza F, Pividori MI, et al. Electrochemical detection of fluoroquinolone antibiotics in milk using a magneto immunosensor. Sensors (Basel) 2014; 14: 15965-80.
86. Gayen P, Chaplin BP. Selective electrochemical detection of ciprofloxacin with a porous nafion/multiwalled carbon nanotube composite film electrode. ACS Appl Mater Interfaces 2016; 8: 1615-26.
87. Theanponkrang S, Suginta W, Weingart H, et al. Robotic voltammetry with carbon nanotube-based sensors: a superb blend for convenient highquality antimicrobial trace analysis. Int J Nanomedicine 2015; 10: 859-68.
88. ZhangF, GuS, DingYet al. A novel sensor based on electropolymerization ofb-cyclodextrin and l-arginine on carbon paste electrode for determination of fluoroquinolones. Anal ChimActa 2013; 770: 53-61.
89. Giroud F, Gorgy K, Gondran C, et al. Impedimetric immunosensor based on a polypyrrole-antibiotic model film for the label-free picomolar detection of ciprofloxacin. Anal Chem 2009; 81: 8405-9.
90. Moraes FC, Silva TA, Cesarino I, et al. Antibiotic detection in urine using electrochemical sensors based on vertically aligned carbon nanotubes. Electroanalysis 2013; 25: 2092-9.
91. Zhang X, Zhang Y-C, Zhang J-W. A highly selective electrochemical sensor for chloramphenicol based on three-dimensional reduced graphene oxide architectures. Talanta 2016; 161: 567-73.
92. Jakubec P, Urbanová V, Med±ríková Zet al. Advanced sensing of antibiotics with magnetic gold nanocomposite: electrochemical detection of chloramphenicol. Chemistry 2016; 22: 14279-84.
93. Govindasamy M, Chen SM, Mani V, et al. Molybdenum disulfide nanosheets coated multiwalled carbon nanotubes composite for highly sensitive determination of chloramphenicol in food samples milk, honey and powderedmilk. J Colloid Interface Sci 2017; 485: 129-36.
94. Karthik R, Govindasamy M, Chen SM, et al. Green synthesized gold nanoparticles decorated graphene oxide for sensitive determination of chloramphenicol in milk, powdered milk, honey and eye drops. J Colloid Interface Sci 2016; 475: 46-56.
95. Meenakshi S, Pandian K, Jayakumari LS, et al. Enhanced amperometric detection ofmetronidazole in drug formulations and urine samples based on chitosan protected tetrasulfonated copper phthalocyanine thin-film modified glassy carbon electrode. Mater Sci Eng C Mater Biol Appl 2016; 59: 136-44.
96. Gan T, Shi Z, Sun J, Liu Y. Simple and novel electrochemical sensor for the determination of tetracycline based on iron/zinc cations-exchanged montmorillonite catalyst. Talanta 2014; 121: 187-93.
97. Liu S, Wang Y, XuWet al. A novel sandwich-type electrochemical aptasensor based on GR-3D Au and aptamer-AuNPs-HRP for sensitive detection of oxytetracycline. Biosens Bioelectron 2017; 88: 181-7.
98. Rastgar S, Shahrokhian S. Nickel hydroxide nanoparticles-reduced graphene oxide nanosheets film: Layer-by-layer electrochemical preparation, characterization and rifampicin sensory application. Talanta 2014; 119: 156-63.
99. Janata J, City SL. pH-based enzyme potentiometric sensors. Anal Chem 1985; 57: 1924-5.
100. Anzai J, Hashimoto J, Osa T, et al. Penicillin sensors based on an ionsensitive coated with stearic acid Langmuir-Blodgett field effect membrane transistor. Anal Sci 1988; 4: 247-50.
101. Yerian TD, Christian GD, Ruzicka J. Flowinjection analysis as a diagnostic technique for development and testing of chemical sensors. Anal Chim Acta 1988; 204: 7-28.
102. Gao X, Zhen R, Zhang Y, Grimes CA. Detecting penicillin in milk with a wireless magnetoelastic biosensor. Sen Lett 2009; 7: 6-10.
103. Wang H, Wang Y, Liu S, et al. Signal-on electrochemical detection of antibiotics at zeptomole level based on target-aptamer binding triggered multiple recycling amplification. Biosens Bioelectron 2016; 80: 471-6.
104. Dapra` J, Lauridsen LH, Nielsen AT, et al. Comparative study on aptamers as recognition elements for antibiotics in a label-free all-polymer biosensor. Biosens Bioelectron 2013; 43: 315-20.
105. Pikkemaat MG. Microbial screening methods for detection of antibiotic residues in slaughter animals. Anal Bioanal Chem2009; 395: 893-905.
106. Huet AC, Delahaut P, Fodey T, et al. Advances in biosensor-based analysis for antimicrobial residues in foods. Trends Anal Chem2010; 29: 1281-94.
107. Willander M, Khun K, Ibupoto ZH. Metal oxide nanosensors using polymeric membranes, enzymes and antibody receptors as ion and molecular recognition elements. Sensors (Switzerland) 2014; 14: 8605-32.
108. Ismail F, Adeloju SB. Galvanostatic entrapment of penicillinase into polytyramine films and its utilization for the potentiometric determination of penicillin. Sensors 2010; 10: 2851-68.
109. Bi X, Hartono D, Yang KL. Real-time liquid crystal pH sensor formonitoring enzymatic activities of penicillinase. Adv Funct Mater 2009; 19: 3760-5.
110. Gonçalves LM, Callera WFA, Sotomayor MDPT, et al. Penicillinase-based amperometric biosensor for penicillin G. Electrochem Commun 2014; 38: 131-3.
111. Müntze GM, Baur B, Schäfer W, et al. Quantitative analysis of immobilized penicillinase using enzyme-modified AlGaN/GaN field-effect transistors. Biosens Bioelectron 2015; 64: 605-10.
112. Siqueira JR, Abouzar MH, Poghossian A, et al. Penicillin biosensor based on a capacitive field-effect structure functionalized with a dendrimer/carbon nanotube multilayer. Biosens Bioelectron 2009; 25: 497-501.
113. Cháfer-Pericás C, Maquieira Á, Puchades R. Fast screening methods to detect antibiotic residues in food samples. Trends Anal Chem 2010; 29: 1038-49.
114. Rowe AA, Miller EA, Plaxco KW. Reagentlessmeasurement of aminoglycoside antibiotics in blood serum via an electrochemical, ribonucleic acid aptamer-based biosensor. Anal Chem2010; 82: 7090-5.
115. Wu X, Kuang H, Hao C, et al. Paper supported immunosensor for detection of antibiotics. Biosens Bioelectron 2012; 33: 309-12.
116. Schoukroun-Barnes LR, Wagan S, White RJ. Enhancing the analytical performance of electrochemical RNA aptamer-based sensors for sensitive detection of aminoglycoside antibiotics. Anal Chem 2014; 86: 1131-7.
117. Han S, Li B, Song Z, et al. A kanamycin sensor based on an electrosynthesized molecularly imprinted poly-o-phenylenediamine film on a single-walled carbon nanohorn modified glassy carbon electrode. Analyst 2016; 142: 218-23.
118. Nikolaus N, Strehlitz B. DNA-aptamers binding aminoglycoside antibiotics. Sensors (Basel) 2014; 14: 3737-55.
119. Chiu M-H, Yang H-H, Liu C-H, et al. Determination of lincomycin in urine and some foodstuffs by flow injection analysis coupledwith liquid chromatography and electrochemical detection with a preanodized screen-printed carbon electrode. J Chromatogr B Analyt Technol BiomedLife Sci 2009; 877: 991-4.
120. ZaccoE, Adrian J, GalveRet al. Electrochemical magneto immunosensing of antibiotic residues inmilk. Biosens Bioelectron 2007; 22: 2184-91.
121. Joseph R, Girish Kumar K. Differential pulse voltammetric determination and catalytic oxidation of sulfamethoxazole using [5,10,15,20-tetrakis (3-methoxy-4-hydroxy phenyl) porphyrinato] Cu (II)modified carbon paste sensor. Drug Test Anal 2010; 2: 278-83.
122. Sgobbi LF, Razzino CA, Machado SAS. A disposable electrochemical sensor for simultaneous detection of sulfamethoxazole and trimethoprim antibiotics in urine based on multiwalled nanotubes decorated with Prussian blue nanocubes modified screen-printed electrode. Electrochim Acta 2016; 191: 1010-7.